⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3281206 | 1.00 | TRPA1 (0.33) | — | |
| SCHEMBL2373370 | 1.00 | — | — | |
| SCHEMBL3281200 | 1.00 | TRPA1 (0.33) | — | |
| SCHEMBL1602300 | 0.97 | TRPA1 (0.32) | — | |
| SCHEMBL1602298 | 0.97 | TRPA1 (0.32) | — | |
| SCHEMBL3306442 | 0.79 | ALDH1A1 (0.33) | — | |
| SCHEMBL10391901 | 0.79 | ALDH1A1 (0.33) | — | |
| SCHEMBL12551237 | 0.79 | MEN1 (0.32) | — | |
| SCHEMBL3052198 | 0.77 | MEN1 (0.32) | — | |
| SCHEMBL3308456 | 0.77 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | claimed |
| EP-1773817-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-20060040966-A1 | e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases | AMGEN INC. | 2006-02-23 | — | — | US | claimed |
| WO-2006012374-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-02-02 | — | — | WO | claimed |
| CN-113540562-B | Electrolyte for lithium battery, and preparation method and application of electrolyte | 中国石油化工股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-116648512-A | Methods, systems, and media for delivering substances to plants | 埃皮杰内蒂卡有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-113540562-A | Electrolyte for lithium battery, lithium battery and preparation method and application thereof | 中国石油化工股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-2958181-B1 | NON-AQUEOUS ELECTROLYTIC SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEM CORP (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9653754-B2 | Nonaqueous electrolytes and nonaqueous-electrolyte secondary batteries employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-05-16 | — | — | US | disclosed |
| US-9620814-B2 | — | — | 2017-04-11 | — | — | US | disclosed |
| US-9515348-B2 | Nonaqueous electrolytic solution and nonaqueous-electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-12-06 | — | — | US | disclosed |
| US-9231277-B2 | Nonaqueous electrolytes and nonaqueous-electrolyte secondary batteries employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-01-05 | — | — | US | disclosed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-7507748-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-03-24 | — | — | US | disclosed |
| WO-2008066558-A2 | PROCESS FOR THE PREPARATION OF 2-SUBSTITUTED-5-(1-ALKYLTHIO)ALKYLPYRIDINES | DOW AGROSCIENCES LLC (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20080132705-A1 | Process for the preparation of 2-substituted-5-(1-alkylthio)alkylpyridines | CORTEVA AGRISCIENCE LLC | 2008-06-05 | — | — | US | disclosed |
| US-20060040966-A1 | e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| US-5466800-A | Process for the preparation of 2,5-disubstituted pyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1995-11-14 | — | — | US | disclosed |
| EP-0584491-B1 | Process for the production of 2,5-disubstituted pyridines | BAYER AG (DE) | 1995-05-03 | — | — | EP | disclosed |
| EP-0584491-A1 | Process for the production of 2,5-disubstituted pyridines | BAYER AG (DE) | 1994-03-02 | — | — | EP | disclosed |